CVS Health Q2 revenue beats estimates, outlook raised

CVS raised its full-year 2026 outlook for EPS and cash flow from operations.

• 2026 GAAP diluted EPS guidance was raised to $6.84-$7.04 from $6.24-$6.44.
• 2026 adjusted EPS guidance was lifted to $7.90-$8.10 from $7.30-$7.50.
• 2026 cash flow from operations guidance was increased to at least $11.5 billion from at least $9.5 billion.

• Health Care Benefits margin recovery - Adjusted operating income rose sharply in the Health Care Benefits segment, driven by improved performance in the Government business and the absence of a prior-year premium deficiency reserve.
• Pharmacy drug mix and brand inflation - Health Services segment revenue grew due to pharmacy drug mix and brand inflation, partially offset by pharmacy client price improvements.
• Rite Aid asset acquisitions - Increased prescription volume in the Pharmacy & Consumer Wellness segment was supported by contributions from Rite Aid asset acquisitions and brand inflation, though offset by regulatory-related price reductions and reimbursement pressure.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 25 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell".

The average consensus recommendation for the healthcare facilities & services peer group is "buy".